There is growing awareness that the long-standing unmet need for specific counting of therapeutic tissue stem cells has been and continues to be a significant impediment to progress in stem cell therapy, gene and gene editing therapies (because targeting tissue stem cells is essential for durable one-time treatments), and drug development (because drug candidates that damage tissue stem cells fail miserably). This year, the listed determination of tissue stem cell-specific dose as a priority for standards development for stem cell clinical trials.
Asymmetrex, headquartered in Boston, Massachusetts has the goal of moving the fields of stem cell science and stem cell medicine into a new quantitative era. 鈥淏ecause of their unique biological properties 鈥 the same ones that make tissue stem cells the remarkable therapeutic agents that they are 鈥 it has not been possible to determine the number of tissue stem cells in any setting,鈥 said Dr. James Sherely, Founder & Director of Asymmetrex, adding, 鈥淣ot in research, not in stem cell biomanufacturing, and not in stem cell medicine.鈥